
    
      This parallel, randomized, open-label study 326 patients with metastatic ( adenocarcinoma of
      the stomach or the esophagogastric junction without previous therapy will be included in this
      study. After randomization patients receive 9 cycles FOLFOX6 or mFOLFIRINOX.

      Stratification factors include ECOG, site of metastasis, age, pathological subtypes.

      Efficacy will be evaluated every 3 cycles with RECIST. Toxicity will be assessed with WHO CTC
      3.0 every 2 weeks.
    
  